Literature DB >> 3029272

In vivo application of recombinant interleukin 2 in the immunotherapy of established cytomegalovirus infection.

M J Reddehase, W Mutter, U H Koszinowski.   

Abstract

We have shown in a murine model system for cytomegalovirus (CMV) disease in the immunocompromised host that in vivo application of recombinant human IL-2 (rhIL-2) can enhance the antiviral effect of a limited number of CD8+T lymphocytes, not only in prophylaxis, but also in therapy, when virus has already colonized host tissues. The observed net effect of IL-2 was consistent with the assumption of daily effector population doublings. The prospects for IL-2-supported immunotherapy of established CMV infection depend upon the tissues involved in disease. It appears that the prospects for controlling established CMV adrenalitis are less promising than for a therapy of interstitial CMV pneumonia.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3029272      PMCID： PMC2188275          DOI： 10.1084/jem.165.3.650

Source DB:  PubMed          Journal:  J Exp Med        ISSN： 0022-1007            Impact factor:   14.307


  14 in total

1.  Interstitial murine cytomegalovirus pneumonia after irradiation: characterization of cells that limit viral replication during established infection of the lungs.

Authors:  M J Reddehase; F Weiland; K Münch; S Jonjic; A Lüske; U H Koszinowski
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

2.  Acquired immunodeficiency syndrome. Clinicopathologic study of 56 autopsies.

Authors:  G W Niedt; R A Schinella
Journal:  Arch Pathol Lab Med       Date:  1985-08       Impact factor: 5.534

3.  Pathogenesis of pulmonary cytomegalovirus infection in immunosuppressed mice.

Authors:  A R Brody; J E Craighead
Journal:  J Infect Dis       Date:  1974-06       Impact factor: 5.226

4.  Congenital cytomegalovirus infection: a fifteen year perspective.

Authors:  J B Hanshaw
Journal:  J Infect Dis       Date:  1971-05       Impact factor: 5.226

5.  Adrenal necrosis in the acquired immunodeficiency syndrome.

Authors:  M L Tapper; H Z Rotterdam; C W Lerner; K Al'Khafaji; P A Seitzman
Journal:  Ann Intern Med       Date:  1984-02       Impact factor: 25.391

6.  Murine cytomegalovirus adrenalitis in athymic nude mice.

Authors:  J D Shanley; E L Pesanti
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

7.  Results of clinical trials with the administration of interleukin 2 and adoptive immunotherapy with activated cells in patients with cancer.

Authors:  M T Lotze; S A Rosenberg
Journal:  Immunobiology       Date:  1986-09       Impact factor: 3.144

8.  Cytomegalovirus infection and specific cell-mediated immunity after marrow transplant.

Authors:  J D Meyers; N Flournoy; E D Thomas
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

9.  Interleukin-2 enhances the depressed natural killer and cytomegalovirus-specific cytotoxic activities of lymphocytes from patients with the acquired immune deficiency syndrome.

Authors:  A H Rook; H Masur; H C Lane; W Frederick; T Kasahara; A M Macher; J Y Djeu; J F Manischewitz; L Jackson; A S Fauci; G V Quinnan
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

10.  Pathogenesis of murine cytomegalovirus infection in natural killer cell-depleted mice.

Authors:  J F Bukowski; B A Woda; R M Welsh
Journal:  J Virol       Date:  1984-10       Impact factor: 5.103
View more
  35 in total

1.  Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65).

Authors:  R Holtappels; J Podlech; N K Grzimek; D Thomas; M F Pahl-Seibert; M J Reddehase
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype.

Authors:  Rafaela Holtappels; Doris Thomas; Jürgen Podlech; Matthias J Reddehase
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Adoptive immunotherapy of murine cytomegalovirus adrenalitis in the immunocompromised host: CD4-helper-independent antiviral function of CD8-positive memory T lymphocytes derived from latently infected donors.

Authors:  M J Reddehase; S Jonjić; F Weiland; W Mutter; U H Koszinowski
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

Review 4.  CD8 T-cell-based immunotherapy of cytomegalovirus infection: "proof of concept" provided by the murine model.

Authors:  Rafaela Holtappels; Verena Böhm; Jürgen Podlech; Matthias J Reddehase
Journal:  Med Microbiol Immunol       Date:  2008-03-15       Impact factor: 3.402

5.  Control of cytomegalovirus in bone marrow transplantation chimeras lacking the prevailing antigen-presenting molecule in recipient tissues rests primarily on recipient-derived CD8 T cells.

Authors:  M Alterio de Goss; R Holtappels; H P Steffens; J Podlech; P Angele; L Dreher; D Thomas; M J Reddehase
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

6.  Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence.

Authors:  H P Steffens; S Kurz; R Holtappels; M J Reddehase
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

Review 7.  Parameters determining the efficacy of adoptive CD8 T-cell therapy of cytomegalovirus infection.

Authors:  Stefan Ebert; Jürgen Podlech; Dorothea Gillert-Marien; Kerstin M Gergely; Julia K Büttner; Annette Fink; Kirsten Freitag; Doris Thomas; Matthias J Reddehase; Rafaela Holtappels
Journal:  Med Microbiol Immunol       Date:  2012-09-13       Impact factor: 3.402

Review 8.  Principles for studying in vivo attenuation of virus mutants: defining the role of the cytomegalovirus gH/gL/gO complex as a paradigm.

Authors:  Jürgen Podlech; Matthias J Reddehase; Barbara Adler; Niels A W Lemmermann
Journal:  Med Microbiol Immunol       Date:  2015-03-18       Impact factor: 3.402

9.  Optic neuritis in different strains of mice by a recombinant HSV-1 expressing murine interleukin-2.

Authors:  Mandana Zandian; Raelene Belisle; Kevin R Mott; Steven Nusinowitz; Florence M Hofman; Homayon Ghiasi
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-02-21       Impact factor: 4.799

10.  Antigen presentation under the influence of 'immune evasion' proteins and its modulation by interferon-gamma: implications for immunotherapy of cytomegalovirus infection with antiviral CD8 T cells.

Authors:  Annette Fink; Niels A W Lemmermann; Dorothea Gillert-Marien; Doris Thomas; Kirsten Freitag; Verena Böhm; Vanessa Wilhelmi; Kurt Reifenberg; Matthias J Reddehase; Rafaela Holtappels
Journal:  Med Microbiol Immunol       Date:  2012-09-09       Impact factor: 3.402
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.